Study details
Enrolling now
Adjuvant Concurrent Immunotherapy and Radiotherapy for Bladder Cancer
Abramson Cancer Center at Penn Medicine
NCT IDNCT06586255ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
10
Study length
about 2 years
Ages
18+
Locations
1 site in PA
What this study is about
Researchers are testing the safety of a treatment combining immunotherapy and radiation therapy for people with bladder cancer. The trial will last about 731 days, and it aims to enroll approximately 10 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Concurrent Immunotherapy and Radiation Therapy
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Procedures
radiation
Body systems
Oncology